Clivunel Inc patents expiration

1. Scenesse patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076555 CLIVUNEL INC Methods of inducing melanogenesis in a subject
Feb, 2025

(1 year, 4 months from now)

US8334265 CLIVUNEL INC Method of treatment of photodermatoses
Mar, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 8, 2026
New Chemical Entity Exclusivity (NCE) Oct 8, 2024

Drugs and Companies using AFAMELANOTIDE ingredient

NCE-1 date: 2023-10-09

Market Authorisation Date: 08 October, 2019

Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)


More Information on Dosage

SCENESSE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic